Stent Grafts Market by Product Type, Indication, Delivery Mechanism, Material, Configuration, End User

List of Tables

The Stent Grafts Market is projected to grow by USD 1,700.04 million at a CAGR of 8.49% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 960.76 million
Estimated Year [2026]	USD 1,040.12 million
Forecast Year [2032]	USD 1,700.04 million
CAGR (%)	8.49%

Stent Grafts Market Introduction

The stent grafts market is anchored by the global shift toward minimally invasive vascular repair for abdominal aortic aneurysm, thoracic aortic aneurysm, aortic dissection, traumatic aortic injury, and selected peripheral vascular conditions. Endovascular aneurysm repair and thoracic endovascular aortic repair have become central treatment pathways because they can reduce surgical trauma, shorten hospital stays, and expand treatment eligibility for older or higher-risk patients when anatomy is suitable.

Demand is supported by population aging, higher use of CT angiography, improved screening in high-risk groups, and steady innovation in low-profile delivery systems, fenestrated and branched stent grafts, conformable graft materials, and enhanced sealing technologies. The market remains clinically rigorous because product selection depends on anatomy, durability, endoleak risk, access-vessel quality, operator experience, and post-procedure surveillance.

Transformative Shifts in the Stent Grafts Landscape

The competitive landscape is being reshaped by the migration from conventional open surgery to image-guided endovascular treatment, particularly in high-volume vascular centers. Physicians are prioritizing devices that improve anatomical fit, reduce graft migration, support complex aortic branch preservation, and simplify deployment in tortuous vessels.

Regulatory and reimbursement pressure is also transforming commercialization. Evidence expectations are rising under frameworks such as the U.S. FDA pathway and the European Medical Device Regulation, while hospitals are assessing total episode cost, reintervention rates, inventory efficiency, and long-term durability. As a result, manufacturers with strong clinical data, physician training programs, quality systems, and reliable supply chains are better positioned than firms competing mainly on price.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is cumulatively influencing the stent graft value chain by improving imaging interpretation, anatomical measurement, case planning, device sizing, and follow-up surveillance. AI-enabled segmentation of CT angiography can help clinicians quantify neck length, angulation, thrombus burden, iliac access, and aneurysm morphology more consistently, supporting better preoperative planning and reducing workflow variation.

AI is also becoming relevant after implantation. Algorithms can support detection of sac expansion, endoleak suspicion, graft migration, and surveillance adherence patterns when integrated with imaging systems and electronic health records. Adoption will depend on validated performance, explainability, cybersecurity, interoperability with hospital workflows, and clinician oversight, as AI remains a decision-support tool rather than a substitute for vascular expertise.

Key Regional Insights for Stent Grafts

Asia-Pacific is one of the most dynamic regions for stent grafts as Japan, China, Australia, India, and South Korea expand endovascular capabilities and invest in advanced imaging. Japan benefits from an older population and established vascular care, while China and India offer large patient pools with increasing diagnosis rates, expanding tertiary hospitals, and broader access to CT angiography. Australia and South Korea show strong adoption of advanced endovascular aneurysm repair in specialist centers, although reimbursement variability and specialist availability continue to influence uptake across emerging markets.

North America remains a leading region due to high procedural maturity, extensive imaging access, strong clinical trial activity, and broad use of EVAR and TEVAR in the United States and Canada. Europe maintains deep clinical expertise across Germany, France, Italy, Spain, and the United Kingdom, although MDR compliance has increased evidence, documentation, and post-market surveillance requirements. Latin America is led by Brazil and Mexico, where private hospitals adopt advanced stent graft devices faster than many public systems. The Middle East, especially GCC markets, is supported by specialty hospitals, cardiovascular investment, and medical tourism, while Africa faces slower adoption due to infrastructure limitations, affordability barriers, uneven imaging access, and trained workforce constraints.

Key Group Insights Across Strategic Markets

ASEAN presents a mixed access environment for stent grafts, with Singapore, Thailand, and Malaysia showing stronger specialist capacity and Indonesia, Vietnam, and the Philippines expanding gradually as imaging infrastructure and vascular programs scale. Procurement decisions often balance clinical performance with affordability, after-sales support, inventory availability, and physician training.

The GCC benefits from high healthcare spending, tertiary hospital investment, and demand for advanced cardiovascular care, making it attractive for premium stent graft systems. The European Union remains evidence-driven and quality-focused under MDR, favoring suppliers with robust technical documentation, post-market surveillance, and registry-supported outcomes. BRICS countries combine large clinical demand with localization priorities, price sensitivity, and expanding public hospital capacity, while G7 markets shape global standards through clinical evidence, reimbursement scrutiny, technology assessment, and innovation adoption. NATO countries are increasingly attentive to resilient medical supply chains, emergency preparedness, cybersecurity, and continuity of critical vascular device access.

Key Country Insights for Stent Grafts

The United States is the most influential stent graft market due to procedure volume, FDA-regulated innovation, specialist networks, clinical trial infrastructure, and reimbursement depth, while Canada emphasizes evidence-based adoption across provincial health systems. Mexico and Brazil are important Latin American growth markets, supported by private hospital demand and improving endovascular expertise, although access differs across public and private care settings.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain major adopters of abdominal and thoracic stent grafts, with Germany benefiting from high hospital capacity and France and the UK emphasizing structured evaluation, clinical guidelines, and reimbursement discipline. Russia maintains demand for aortic repair but faces procurement, sanctions-related, and supply continuity complexities. China is scaling rapidly through hospital modernization, physician training, and domestic device development, while India is expanding from major metropolitan centers as diagnostic access improves. Japan remains advanced and aging-driven, Australia has strong specialist adoption supported by organized vascular care, and South Korea combines high technology readiness with sophisticated cardiovascular and imaging infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically differentiated devices that address hostile neck anatomy, iliac access challenges, branch preservation, sealing reliability, and long-term durability. Investment in fenestrated, branched, lower-profile, and conformable stent graft systems should be paired with rigorous evidence generation, real-world data, and transparent post-market surveillance.

Commercial success will depend on physician education, case-planning support, local reimbursement strategy, regulatory readiness, and supply reliability. Manufacturers should build AI-ready digital planning ecosystems, partner with imaging and hospital IT providers, and create region-specific portfolios that balance premium innovation with cost-sensitive access. Leaders should also strengthen recall readiness, quality systems, cybersecurity controls, and regulatory documentation to meet expanding global scrutiny.

Research Methodology

The research approach combines primary and secondary intelligence to evaluate market direction, technology adoption, regulatory dynamics, clinical practice patterns, and regional demand drivers. Secondary inputs include public health datasets, regulatory databases, clinical guidelines, device approval records, hospital procurement signals, peer-reviewed literature, company filings, and vascular surgery registry information where available.

Primary validation is conducted through structured discussions with vascular surgeons, interventional radiologists, hospital procurement leaders, distributors, payers, and device. Findings are triangulated across clinical practice, commercial activity, reimbursement conditions, regulatory requirements, and macroeconomic indicators to ensure balanced, data-backed conclusions. AI-related insights are assessed through documented medical imaging use cases, regulatory trends, validated clinical workflow applications, and practical hospital integration relevance.

Conclusion

The stent grafts market is positioned for sustained relevance as healthcare systems continue to favor less invasive vascular repair, earlier diagnosis, and outcomes-based device selection. Demand is strongest where aging populations, imaging infrastructure, specialist expertise, clinical evidence, and reimbursement support align.

Future leadership will be determined by clinical durability, anatomical versatility, regulatory excellence, digital planning integration, quality assurance, and regional. Organizations that combine proven device performance with AI-supported workflows, strong physician partnerships, robust post-market surveillance, and resilient supply chains will be best placed to address demand across mature and emerging stent graft markets.

Product Code: MRR-03147A7F3DEB

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Stent Grafts Market, by Product Type

7.1. Aortic
- 7.1.1. Abdominal Aneurysm
- 7.1.2. Thoracic Aneurysm
7.2. Peripheral

8. Stent Grafts Market, by Indication

8.1. Aneurysm Repair
- 8.1.1. Abdominal
- 8.1.2. Thoracic
8.2. Peripheral Vascular Disease

9. Stent Grafts Market, by Delivery Mechanism

9.1. Balloon Expandable
9.2. Self Expandable

10. Stent Grafts Market, by Material

10.1. ePTFE
10.2. Polyester

11. Stent Grafts Market, by Configuration

11.1. Bifurcated
11.2. Branched
11.3. Straight

12. Stent Grafts Market, by End User

12.1. Ambulatory Surgical Centers
12.2. Hospitals

13. Stent Grafts Market, by Region

13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa

14. Stent Grafts Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Stent Grafts Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. Competitive Landscape

16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025

17. Company Profiles

17.1. B. Braun Melsungen AG
17.2. Becton, Dickinson and Company
17.3. Bentley InnoMed GmbH
17.4. Boston Scientific Corporation
17.5. Braile Biomedica
17.6. Cardinal Health, Inc.
17.7. Cook Medical LLC
17.8. CORCYM, Inc.
17.9. Cryolife Inc.
17.10. Edwards Lifesciences Corporation
17.11. Endospan Ltd.
17.12. InSitu Technologies Inc.
17.13. Jotec GmbH
17.14. Kawasumi Laboratories, Inc.
17.15. LeMaitre Vascular, Inc.
17.16. Lifetech Scientific (Shenzhen) Co., Ltd.
17.17. Medtronic PLC
17.18. MicroPort Scientific Corporation
17.19. Terumo Corporation
17.20. W. L. Gore & Associates, Inc.